Compare Enveric Biosciences Inc (ENVB) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs KB Financial Group, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while KB Financial Group, Inc. trades at $122.32 (market cap $41.90B). The key difference: KB Financial Group, Inc. is far larger — about 7875.9× Enveric Biosciences Inc's market cap, and KB Financial Group, Inc. pays a 2.58% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KB | |
|---|---|---|
Market Cap | $5.32M | $41.90B |
Sector | Health | Financials |
52-Week High | $17.40 | $123.25 |
52-Week Low | $1.28 | $77.50 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
KB Financial Group's stock trades at $121.02, showing modest daily gains. The technical outlook is bullish with strong moving average signals, though oscillators are neutral. Fundamentally, the company demonstrates consistent revenue and net income growth, with a trailing P/E of 11.69 and strong net margin of 27.82%. Recent quarterly earnings have consistently beaten expectations, and the company is diversifying into non-banking operations, which now contribute 43% of earnings according to Seeking Alpha (2026-07-09).
The outlook is positive with earnings momentum and strategic diversification providing stability, though risks include potential overbought technical conditions and execution challenges in non-banking expansion. Analyst sentiment is mixed with a 33% buy rating, indicating cautious optimism about the company's growth trajectory and capital distribution plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
